Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
:MRUS
MRUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.19 - $61.61
Previous CloseN/A
Volume56.75K
Average Volume (3M)808.54K
Market Cap
$2.90B
Enterprise Value$2.37B
Total Cash (Recent Filing)-$1.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 13, 2025EPS Estimate
-1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding69,090,470
10 Day Avg. Volume1,158,685
30 Day Avg. Volume808,540
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)90.33
Price to Cash Flow (P/CF)-12.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit65.49
Enterprise Value/Ebitda-8.16
Forecast
1Y Price Target
$89.31Price Target Upside112.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Merus News
See All MRUS News
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPetosemtamab continues to show impressive efficacy and safety in HNSCC indications, now with breakthrough therapy and fast-track designations in both 1L and 2L+ settings.
Financial PositionThe company reported cash and cash equivalents of $724mn, which they estimate will provide a cash runway into 2028.
Bears Say
Clinical UncertaintyThere remains uncertainty regarding the trigger for the primary ORR analysis, which could impact timelines.
Patient EnrollmentA possible bias against enrolling HPV+ patients onto LiGeR-HN2 in the US is noted, given heavier 1L taxane use and cetuximab's lack of efficacy in HPV+.
---
Ownership Overview
0.40% Insiders
20.54% Mutual Funds
60.69% Other Institutional Investors
16.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $33.19 and its highest was $61.61 in the past 12 months.
What is Merus NV’s market cap?
Merus NV’s market cap is $2.90B.
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is May 13, 2025 which is in 29 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Feb 27, 2025. The company reported -$0.465 earnings per share for the quarter, beating the consensus estimate of -$0.89 by $0.425.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -1.09.
How many shares outstanding does Merus NV have?
Merus NV has 69,090,470 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$0.465 in its last earnings report, beating expectations of -$0.89. Following the earnings report the stock price went up 1.882%.
Which hedge fund is a major shareholder of Merus NV?
Currently, no hedge funds are holding shares in MRUS
---
Merus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.31 (112.79% Upside)
$89.31 (112.79% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 352.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $194.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.59%
12-Months-Change
Fundamentals
Return on Equity
-42.88%
Trailing 12-Months
Asset Growth
71.24%
Trailing 12-Months
Company Description
Merus NV
Merus N.V. (MRUS) is a clinical-stage oncology company that is engaged in the development of innovative multispecific antibody therapeutics. The company focuses on creating bispecific antibodies, known as Biclonics, for the treatment of various types of cancer. These products are designed to engage multiple targets simultaneously, offering a novel approach to cancer therapy.
---
MRUS Stock 12 Month Forecast
Average Price Target
$89.31
▲(112.79% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crispr Therapeutics AG
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Best Analysts Covering MRUS
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+56.78%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +56.78% per trade.
---